Item 5. Other Information
Item 5. Other Information
None.
Item 6. Exhibits
See the Exhibit Index immediately preceding the signature page to this Quarterly Report on Form 10-Q for a list of exhibits filed or furnished with this report, which Exhibit Index is incorporated herein by reference.
72
Table of Contents
EXHIBIT INDEX
2.1*† Sale and Purchase Agreement, executed June 21, 2021, by and between uniQure N.V. and Corlieve Therapeutics SAS
3.1* Amended Articles of Association of the Company, effective as of June 16, 2021.
4.1*t 2014 Share Incentive Plan, Amended and Restated, effective as of June 16, 2021.
10.1*t Employment Agreement, effective May 17, 2021, by and between uniQure biopharma B.V. and Pierre Caloz
10.2*t Equity Side Letter, effective May 17, 2021, by and between uniQure N.V. and Pierre Caloz
10.3*t Amended and Restated Employment Agreement, effective June 15, 2021, by and between uniQure biopharma B.V. and Christian Klemt
31.1* Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer
31.2* Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer
32.1± Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101* The following financial information from our Quarterly Report on Form 10-Q for the period ended June 30, 2021, filed with the Securities and Exchange Commission on July 26, 2021, is formatted in Inline Extensible Business Reporting Language (“iXBRL”): (i) Consolidated Balance Sheets; (ii) Consolidated Statements of Operations and Comprehensive Loss; (iii) Consolidated Statements of Shareholders’ Equity; (iv) Consolidated Statements of Cash Flows; and (v) Notes to Consolidated Financial Statements (tagged as blocks of text)
104* The cover page from our Quarterly Report on Form 10-Q for the period ended June 30, 2021, filed with the Securities and Exchange Commission on July 26, 2021, is formatted in Inline Extensible Business Reporting Language (“iXBRL”)
† Portions of this exhibit (indicated by asterisks) have been omitted in accordance with the rules of the Securities and Exchange Commission.
* Filed herewith.
± Furnished herewith.
t Indicates a management contract or compensatory plan or arrangement
73
Table of Contents
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
UNIQURE, N.V.
By: /s/ Matthew Kapusta
Matthew Kapusta
Chief Executive Officer
(Principal Executive Officer)
By: /s/ Christian Klemt
Christian Klemt
Chief Financial Officer
(Principal Financial Officer)
Dated July 26, 2021
74
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the is authoritative for anything you rely on.